Solid Biosciences Inc. Common Stock
SLDBSolid Biosciences Inc. is a biotechnology company focused on developing gene therapy and other innovative treatments for Duchenne muscular dystrophy (DMD), a rare genetic neuromuscular disorder. The company's pipeline aims to address the underlying genetic causes of DMD and improve quality of life for patients through advanced therapeutic approaches.
Company News
U.S. Department of Health and Human Services added Duchenne muscular dystrophy to the Recommended Uniform Screening Panel, which is expected to accelerate early detection and improve patient outcomes.
Solid Biosciences received FDA Rare Pediatric Disease designation for SGT-212, a dual-route gene therapy targeting Friedreich's ataxia. The therapy aims to restore frataxin protein levels and address neurologic, cardiac, and systemic disease manifestations.
Solid Biosciences has signed a non-exclusive worldwide license agreement with Andelyn Biosciences to provide access to its proprietary AAV-SLB101 gene therapy capsid, expanding collaborative efforts to over 30 agreements.
Solid Biosciences will participate in two healthcare investor conferences in November and December 2025, featuring presentations by its President/CEO and Chief Medical Officer, with live webcasts available.
Solid Biosciences awarded 55,450 restricted stock units to four newly hired employees, with vesting over four years, under their 2024 Inducement Stock Incentive Plan.
